Filings Worth Watching: Pfizer INC (PFE) Shareholder Convergence Investment Partners LLC Boosted Position

Filings Worth Watching: Pfizer INC (PFE) Shareholder Convergence Investment Partners LLC Boosted Position

Convergence Investment Partners Llc increased its stake in Pfizer Inc (PFE) by 137.47% based on its latest 2016Q3 regulatory filing with the SEC. Convergence Investment Partners Llc bought 180,493 shares as the company’s stock declined 4.78% while stock markets rallied. The institutional investor held 311,786 shares of the health care company at the end of 2016Q3, valued at $10.56 million, up from 131,293 at the end of the previous reported quarter. Convergence Investment Partners Llc who had been investing in Pfizer Inc for a number of months, seems to be bullish on the $202.87B market cap company. The stock decreased 0.09% or $0.03 during the last trading session, hitting $33.44. Pfizer Inc. (NYSE:PFE) has declined 4.02% since June 7, 2016 and is downtrending. It has underperformed by 11.44% the S&P500.

Convergence Investment Partners Llc, which manages about $492.68 million and $677.66 million US Long portfolio, decreased its stake in Gilead Sciences Inc (NASDAQ:GILD) by 58,696 shares to 42,554 shares, valued at $3.37 million in 2016Q3, according to the filing.

Convergence Investment Partners Llc is a Wisconsin-based institutional investor with more than $492.68 million AUM in March, 2014. Taken from Convergence Investment Partners latest Adv, the fund reported to have 5 full and part-time employees. Among which 5 performing investment advisory and research functions. The institutional investor had more than 300 clients.

Insitutional Activity: The institutional sentiment increased to 1.18 in Q3 2016. Its up 0.15, from 1.03 in 2016Q2. The ratio increased, as 72 funds sold all PFE shares owned while 634 reduced positions. 117 funds bought stakes while 717 increased positions. They now own 4.08 billion shares or 1.72% less from 4.15 billion shares in 2016Q2. Signature Investment Advsrs Lc, a California-based fund reported 4,597 shares. Zacks Inv has 1.79% invested in the company for 1.87M shares. New England Rech And Incorporated accumulated 59,067 shares or 1.68% of the stock. Frontier Inv Mngmt accumulated 0% or 32,093 shares. Markston holds 213,441 shares or 0.68% of its portfolio. Atlantic Tru Limited Liability Company, a Georgia-based fund reported 899,831 shares. Strategy Asset Managers Llc last reported 2.27% of its portfolio in the stock. Acropolis Investment Mngmt Limited Co accumulated 7,107 shares or 0.04% of the stock. Palisade Cap Mgmt Ltd Liability Corporation Nj last reported 0.3% of its portfolio in the stock. Btc Capital Mngmt accumulated 0.83% or 117,333 shares. The New York-based Allsquare Wealth Management Lc has invested 0.34% in Pfizer Inc. (NYSE:PFE). Fjarde Ap accumulated 1.43M shares or 1.06% of the stock. Country Club Na last reported 297,150 shares in the company. Ing Groep Nv holds 2.22M shares or 0.89% of its portfolio. Jpmorgan Chase And Company owns 114.73 million shares or 0.96% of their US portfolio.

Insider Transactions: Since November 4, 2016, the stock had 0 insider purchases, and 2 sales for $882,530 net activity. MADDALUNA ANTHONY J also sold $330,000 worth of Pfizer Inc. (NYSE:PFE) on Wednesday, November 9. BOURLA ALBERT also sold $552,530 worth of Pfizer Inc. (NYSE:PFE) shares.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: which released: “Pfizer Inc.: Humira’s Biosimilar Meets Primary Endpoint” on January 10, 2017, also with their article: “Better Buy: Pfizer Inc. vs. Merck” published on December 14, 2016, published: “4 Reasons Why Pfizer Inc. Stock (PFE) Could be a Great Pick in 2017” on January 04, 2017. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: and their article: “Pfizer talks shop at JPMorgan conference; cancels breakout session” published on January 10, 2017 as well as‘s news article titled: “Acadia Pharmaceuticals Inc. (ACAD) Flirts With a Pfizer Inc. (PFE) Buyout” with publication date: January 04, 2017.

According to Zacks Investment Research, “Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer’s Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.”

Pfizer Inc. (NYSE:PFE) Ratings Coverage

Out of 19 analysts covering Pfizer (NYSE:PFE), 8 rate it a “Buy”, 0 “Sell”, while 11 “Hold”. This means 42% are positive. $51 is the highest target while $34 is the lowest. The $39.29 average target is 17.49% above today’s ($33.44) stock price. Pfizer has been the topic of 40 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The stock has “Hold” rating given by Societe Generale on Wednesday, April 6. On Tuesday, October 20 the stock rating was upgraded by Cowen & Co to “Outperform”. The stock of Pfizer Inc. (NYSE:PFE) has “Overweight” rating given on Friday, August 28 by Piper Jaffray. S&P Research maintained it with “Hold” rating and $40 target price in Wednesday, October 28 report. Suntrust Robinson upgraded it to “Neutral” rating and $37 target price in Wednesday, November 25 report. The firm earned “Neutral” rating on Wednesday, November 25 by SunTrust. Argus Research maintained Pfizer Inc. (NYSE:PFE) rating on Tuesday, November 3. Argus Research has “Buy” rating and $46 price target. The firm earned “Overweight” rating on Friday, October 2 by Morgan Stanley. The stock has “Hold” rating given by Jefferies on Thursday, October 13. Jefferies maintained Pfizer Inc. (NYSE:PFE) on Tuesday, June 14 with “Buy” rating.

PFE Company Profile

Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research global biopharmaceutical company. The Firm is engaged in discovering, developing and manufacturing of healthcare products. The Company’s divisions include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The Company’s portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. The Company’s biopharmaceutical products include Lipitor, Sutent and the Premarin family of products. The Company’s biotechnology products include BeneFIX, ReFacto and Xyntha.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Reply

Be the First to Comment!

Notify of